查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447073

到 2030 年結直腸癌市場預測：按方式、最終用戶和地區進行的全球分析

Colorectal Cancer Market Forecasts to 2030 - Global Analysis By Modility (Diagnosis Type, Therapy Type and Other Modilities), End User(Hospitals, Diagnostic and Research Laboratories and Other End Users) and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球大腸癌市場規模為 196 億美元，預計預測期內年複合成長率為 5.30%，到 2030 年將達到 281 億美元。

大腸直腸癌是一種在結腸和直腸中發生的惡性，結腸和直腸是消化器官系統的一部分。它通常始於稱為息肉的小型非癌性生長，並隨著時間的推移逐漸轉變為癌症。症狀包括飲食習慣改變、血便、腹部不適和體重意外減輕。大腸鏡檢查等篩檢測試可以幫助在息肉癌變之前發現並切除息肉，從而增加早期發現和成功治療的機會。

根據世界衛生組織（WHO）統計，大腸直腸癌的發生率位居癌症第三位，2020年全球約有193萬人患有大腸癌，到2030年，全球大腸癌病例數還將增加。預計人數將增加約70%。根據國際癌症研究機構和 GLOBOCAN 的數據，預計 2020 年亞洲大腸癌發生率約為 1,009,400 例。

聯合研究工作

合作研究是促進研究人員、醫療機構和製藥公司之間協同效應的重要驅動力。這些合作能夠共用資源、專業知識和資料，以加速創新治療方法和診斷工具的發現和發展。透過共用見解和最佳實踐，研究人員正在發現新的生物標記、治療標靶和治療方法，最終改善患者的治療結果。此外，合作研究促進了調查方法和臨床試驗通訊協定的標準化，從而產生穩健可靠的資料。

目前治療方法的效果有限

目前大腸直腸癌市場上的治療方法效果有限是由多種因素造成的。存在手術、化療和標靶治療，但它們具有顯著的副作用，並且往往並非對所有患者有效，特別是那些患有晚期疾病或具有某些基因突變的患者。隨著時間的推移，抗藥性會產生並降低治療效果。大腸直腸癌的複雜性和異質性也對開發針對個別患者的有效治療方法提出了挑戰。此外，目前的情況突顯需要繼續研究和開發新的治療方法以改善大腸直腸癌患者的預後。

生物標記開發

生物標記為大腸直腸癌患者的早期檢測、準確診斷、預後預測和治療效果監測提供了可能。基於生物標記的檢測可以透過識別適當的患者群體、加速藥物開發和降低成本來簡化臨床試驗。將生物標記納入常規篩檢計畫有可能提高大腸癌篩檢的效率、減輕醫療保健系統的負擔並改善資源分配。此外，大腸直腸癌生物標記的開發為推動精準醫療和改善這種常見惡性的治療提供了一條有希望的途徑。

生物相似藥的出現

生物相似藥的出現構成了重大威脅，因為它們有可能以較低的成本提供相同的功效。生物相似藥是一種與已核准的生物製藥相似的產品，一旦原廠產品的專利到期即可進入市場。因此，生物相似藥為患者提供了更便宜的治療選擇。由於生物相似藥可以以較低的價格提供類似的功效，因此它們可能會威脅原廠生物製藥的市場力量，並減少現有大腸直腸癌治療的市場佔有率。這種競爭可能會壓低價格，迫使品牌藥廠調整其定價策略，否則將面臨市場佔有率下降。

COVID-19 的影響：

COVID-19 大流行以多種方式對大腸癌市場產生了重大影響。由於醫療保健資源的排除和重新分配而導致篩檢和診斷程序的延遲，導致早期檢測減少，並可能導致晚期診斷。治療的取得和依從性也受到影響，導致治療週期和病患管理中斷。供應鏈中斷和臨床試驗延遲阻礙了新治療方法的開發和可用性。儘管有這些挑戰，遠端醫療和創新護理服務模式的使用已經出現，有助於減輕一些影響。這突顯出需要有彈性的醫療保健系統，即使在危機情況下也能管理癌症治療。

預計在預測期內最大的治療類型

由於治療方法的進步，治療類型正在顯著成長。這一成長是由擴大採用標靶治療、免疫療法和聯合治療推動的，與傳統化療相比，這些療法可提高療效並減少副作用。生物標記測試等精準醫學方法的發展使得針對每個患者的基因譜量身定做更個性化的治療策略成為可能。此外，正在進行的探索新治療藥物和治療方法組合的研究和臨床試驗也正在推動這一領域的創新和擴張。

診斷和研究測試產業預計在預測期內年複合成長率最高

由於診斷技術的進步和對早期檢測的興趣的增加，診斷和研究實驗室領域正在經歷顯著的成長。這些實驗室在分子測定和液態切片等創新診斷測試的開發和檢驗中發揮關鍵作用，這些測試在結直腸癌生物標記的檢測中提供了更高的靈敏度和特異性。旨在闡明結直腸癌進展的潛在機制的研究投資的增加正在刺激對檢測服務的需求。此外，人工智慧和機器學習演算法在資料分析中的整合正在提高這些實驗室診斷過程的準確性和效率。

比最大的地區

由於人們對早期檢測和篩檢計劃重要性的認知不斷提高、診斷技術的進步以及人口老化，北美結直腸癌市場正在經歷強勁成長。醫療保健服務的改善和有利的報銷政策有助於市場擴張。製藥公司也積極開發創新治療方法和治療方法，進一步促進成長。總體而言，北美地區繼續發揮關鍵作用，持續努力改善患者治療結果並降低死亡率。

年複合成長率最高的地區：

由於生活方式改變、飲食習慣和人口老化等因素導致大腸直腸癌發病率上升，亞太地區大腸直腸癌市場正在經歷顯著成長。提高認知宣傳活動、改進篩檢計劃以及診斷技術的進步正在促進早期發現和治療。該地區許多國家不斷擴大的醫療基礎設施和不斷上升的醫療成本正在推動大腸癌治療的需求。此外，政府、醫療保健組織和製藥公司之間為解決大腸癌負擔而進行的合作也在推動亞太地區市場成長方面發揮著至關重要的作用。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球大腸直腸癌市場：依方式分類

  • 診斷類型
    • 免疫組織化學
    • 糞便檢驗
    • 軟式乙狀結腸鏡檢查
    • 大腸鏡檢查
    • CEA測試
    • 其他診斷類型
  • 治療類型
    • 化療
      • 烷化劑
      • 抗代謝物
      • 其他化療
    • 免疫療法
      • Panitumumab
      • Cetuximab
      • Bevacizumab
      • 其他免疫療法
    • 其他治療方法
  • 影像類型
    • 電腦斷層掃描 (CT)
    • 磁振造影(MRI)
    • 其他圖像類型
  • 其他方式

第6章全球大腸直腸癌市場：依最終用戶分類

  • 醫院
  • 診斷和研究機構
  • 其他最終用戶

第7章全球大腸直腸癌市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Abbott Diagnostics
  • Alaunos Therapeutics Inc
  • Alere
  • Beckman Coulter
  • Bristol-Myers Squibb Co,
  • Clinical Genomics
  • Debiopharm Group
  • F-Hoffmann-La Roche Ltd,
  • Immunovative Therapies Ltd
  • Iovance Biotherapeutics,
  • Replimune Group
  • Transgene SA
  • Turnstone Biologics Inc.
  • Vaccinogen BD
Product Code: SMRC25334

According to Stratistics MRC, the Global Colorectal Cancer Market is accounted for $19.60 billion in 2023 and is expected to reach $28.10 billion by 2030 growing at a CAGR of 5.30% during the forecast period. Colorectal cancer is a malignant tumor that develops in the colon or rectum, which are parts of the digestive system. It usually begins as small, noncancerous growths called polyps that can gradually transform into cancer over time. Symptoms may include changes in bowel habits, blood in the stool, abdominal discomfort, and unintended weight loss. Screening tests such as colonoscopies can help detect and remove polyps before they become cancerous, increasing the chances of early detection and successful treatment.

According to the World Health Organization (WHO), colorectal cancer is the third most prevalent form of cancer, with ~1.93 million global cases in 2020, and an increase of ~70% in colorectal cancer cases worldwide is expected by 2030. According to the International Agency for Research on Cancer & GLOBOCAN, the estimated incidence of colorectal cancer in Asia reported ~1,009,400 new cases in 2020.

Market Dynamics:

Driver:

Collaborative research efforts

Collaborative research efforts serve as a significant driver by fostering synergy among researchers, healthcare institutions, and pharmaceutical companies. These collaborations enable the pooling of resources, expertise, and data, expediting the discovery and development of innovative treatments and diagnostic tools. By sharing insights and best practices, researchers are uncovering novel biomarkers, therapeutic targets, and treatment modalities, ultimately enhancing patient outcomes. Furthermore, collaborative efforts promote the standardization of research methodologies and clinical trial protocols, ensuring robust and reliable data generation.

Restraint:

Limited efficacy of current treatments

The limited efficacy of current treatments in the colorectal cancer market arises due to several factors. While surgeries, chemotherapy, and targeted therapies exist, they often come with significant side effects and may not be effective for all patients, particularly those with advanced stages of the disease or certain genetic mutations. Drug resistance can develop over time, reducing the effectiveness of treatments. The complexity and heterogeneity of colorectal cancer also pose challenges in developing effective treatments tailored to individual patients. Additionally, the current landscape highlights the need for continued research and development of novel therapies to improve outcomes for colorectal cancer patients.

Opportunity:

Biomarker development

Biomarkers offer the potential for early detection, accurate diagnosis, prognosis prediction, and monitoring of treatment response in colorectal cancer patients. Biomarker-based assays could streamline clinical trials by identifying suitable patient populations, expediting drug development, and reducing costs. The integration of biomarkers into routine screening programs could enhance the efficiency of colorectal cancer detection, potentially reducing the burden on healthcare systems and improving resource allocation. Furthermore, biomarker development in colorectal cancer represents a promising avenue for advancing precision medicine and improving the management of this prevalent malignancy.

Threat:

Emergence of biosimilars

The emergence of biosimilars poses a significant threat due to their potential to offer comparable efficacy at lower costs. Biosimilars are highly similar versions of already-approved biologic drugs that can enter the market once the patents on the original drugs expire. As a result, they provide patients with more affordable treatment options. This threatens the market dominance of originator biologics, as biosimilars can offer similar benefits at reduced prices, potentially leading to market share erosion for established colorectal cancer treatments. This competition may drive down prices, forcing original drug manufacturers to adjust their pricing strategies or face decreased market share.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the colorectal cancer market on multiple fronts. Delayed screenings and diagnostic procedures due to lockdowns and healthcare resource reallocations led to a decline in early detections, potentially resulting in advanced-stage diagnoses. Treatment access and adherence were also affected, causing disruptions in therapy cycles and patient management. Supply chain interruptions and clinical trial delays hampered the development and availability of new therapies. Despite these challenges, telemedicine utilization and innovative care delivery models emerged to mitigate some of the impacts, emphasizing the need for resilient healthcare systems to manage cancer care during crises.

The therapy type segment is expected to be the largest during the forecast period

The therapy type segment has shown significant growth due to advancements in treatment modalities. This growth can be attributed to the increasing adoption of targeted therapies, immunotherapies, and combination treatments, which offer improved efficacy and reduced side effects compared to traditional chemotherapy. The development of precision medicine approaches, such as biomarker testing, has allowed for more personalized treatment strategies tailored to individual patients' genetic profiles. Additionally, ongoing research efforts and clinical trials exploring novel therapeutic agents and treatment combinations continue to drive innovation and expansion within this segment.

The diagnostic and research laboratories segment is expected to have the highest CAGR during the forecast period

The Diagnostic and Research Laboratories segment in has experienced substantial growth due to advancements in diagnostic technologies and an increased focus on early detection. These laboratories play a crucial role in the development and validation of innovative diagnostic tests, such as molecular assays and liquid biopsies, which offer higher sensitivity and specificity in detecting colorectal cancer biomarkers. Rising investments in research aimed at understanding the underlying mechanisms of colorectal cancer progression which have fuelled demand for laboratory services. Additionally, the integration of artificial intelligence and machine learning algorithms in data analysis has enhanced the accuracy and efficiency of diagnostic processes in these laboratories.

Region with largest share:

North American region has seen robust growth in the colorectal cancer market, driven by increasing awareness about the importance of early detection and screening programs, advancements in diagnostic technologies, and a growing aging population. Improved access to healthcare services and favorable reimbursement policies have contributed to the expansion of the market. Pharmaceutical companies have also been actively developing innovative treatments and therapies, further fueling growth. Overall, the North American region continues to be a key player, with sustained efforts towards improving patient outcomes and reducing mortality rates.

Region with highest CAGR:

The Asia-Pacific region has witnessed significant growth in the colorectal cancer market due to rising incidence rates of colorectal cancer, attributed to factors such as lifestyle changes, dietary habits, and an aging population. Increased awareness campaigns, improved screening programs, and advancements in diagnostic technologies have facilitated early detection and treatment. Expanding healthcare infrastructure and increasing healthcare expenditures across many countries in the region have fueled the demand for colorectal cancer treatments and therapies. Additionally, collaborations between governments, healthcare organizations, and pharmaceutical companies to address the burden of colorectal cancer have also played a pivotal role in driving market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Colorectal Cancer market include Abbott Diagnostics, Alaunos Therapeutics Inc, Alere, Beckman Coulter, Bristol-Myers Squibb Co, Clinical Genomics, Debiopharm Group, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Iovance Biotherapeutics, Replimune Group, Transgene SA , Turnstone Biologics Inc. and Vaccinogen BD.

Key Developments:

In August 2023, Redcliffe Labs has partnered with Abbott India to launch Clinical Decision Support (CDS), also known as AlinIQ, which is powered by unique technologies such as Big Data Engines and Artificial Intelligence (AI). This game-changing advancement intends to revolutionise healthcare by providing potential solutions to improve patient care and ease.

In March 2023, Scailyte AG announced that it entered into collaboration with Turnstone Biologics to discover signature biomarkers predictive of clinical responses to tumor-infiltrating lymphocyte (TIL) therapy by applying ScaiVision, Scailyte's best-in-class single-cell sequencing analytical platform.

Modilities Covered:

  • Diagnosis Type
  • Therapy Type
  • Imaging Type
  • Other Modilities

End Users Covered:

  • Hospitals
  • Diagnostic and Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Colorectal Cancer Market, By Modility

  • 5.1 Introduction
  • 5.2 Diagnosis Type
    • 5.2.1 Immunohistochemistry
    • 5.2.2 Stool Test
    • 5.2.3 Flexible Sigmoidoscopy
    • 5.2.4 Colonoscopy
    • 5.2.5 CEA Test
    • 5.2.6 Other Diagnosis Types
  • 5.3 Therapy Type
    • 5.3.1 Chemotherapy
      • 5.3.1.1 Alkylating Agent
      • 5.3.1.2 Antimetabolites
      • 5.3.1.3 Other Chemotherapies
    • 5.3.2 Immunotherapy
      • 5.3.2.1 Panitumumab
      • 5.3.2.2 Cetuximab
      • 5.3.2.3 Bevacizumab
      • 5.3.2.4 Other Immunotherapies
    • 5.3.3 Other Therapy Types
  • 5.4 Imaging Type
    • 5.4.1 Computed Tomography (CT)
    • 5.4.2 Magnetic Resonance Imaging (MRI)
    • 5.4.3 Other Imaging Types
  • 5.5 Other Modilities

6 Global Colorectal Cancer Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Diagnostic and Research Laboratories
  • 6.4 Other End Users

7 Global Colorectal Cancer Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abbott Diagnostics
  • 9.2 Alaunos Therapeutics Inc
  • 9.3 Alere
  • 9.4 Beckman Coulter
  • 9.5 Bristol-Myers Squibb Co,
  • 9.6 Clinical Genomics
  • 9.7 Debiopharm Group
  • 9.8 F-Hoffmann-La Roche Ltd,
  • 9.9 Immunovative Therapies Ltd
  • 9.10 Iovance Biotherapeutics,
  • 9.11 Replimune Group
  • 9.12 Transgene SA
  • 9.13 Turnstone Biologics Inc.
  • 9.14 Vaccinogen BD

List of Tables

  • Table 1 Global Colorectal Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Colorectal Cancer Market Outlook, By Modality (2021-2030) ($MN)
  • Table 3 Global Colorectal Cancer Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 4 Global Colorectal Cancer Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 5 Global Colorectal Cancer Market Outlook, By Stool Test (2021-2030) ($MN)
  • Table 6 Global Colorectal Cancer Market Outlook, By Flexible Sigmoidoscopy (2021-2030) ($MN)
  • Table 7 Global Colorectal Cancer Market Outlook, By Colonoscopy (2021-2030) ($MN)
  • Table 8 Global Colorectal Cancer Market Outlook, By CEA Test (2021-2030) ($MN)
  • Table 9 Global Colorectal Cancer Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 10 Global Colorectal Cancer Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 11 Global Colorectal Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 12 Global Colorectal Cancer Market Outlook, By Alkylating Agent (2021-2030) ($MN)
  • Table 13 Global Colorectal Cancer Market Outlook, By Antimetabolites (2021-2030) ($MN)
  • Table 14 Global Colorectal Cancer Market Outlook, By Other Chemotherapies (2021-2030) ($MN)
  • Table 15 Global Colorectal Cancer Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 16 Global Colorectal Cancer Market Outlook, By Panitumumab (2021-2030) ($MN)
  • Table 17 Global Colorectal Cancer Market Outlook, By Cetuximab (2021-2030) ($MN)
  • Table 18 Global Colorectal Cancer Market Outlook, By Bevacizumab (2021-2030) ($MN)
  • Table 19 Global Colorectal Cancer Market Outlook, By Other Immunotherapies (2021-2030) ($MN)
  • Table 20 Global Colorectal Cancer Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 21 Global Colorectal Cancer Market Outlook, By Imaging Type (2021-2030) ($MN)
  • Table 22 Global Colorectal Cancer Market Outlook, By Computed Tomography (CT) (2021-2030) ($MN)
  • Table 23 Global Colorectal Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 24 Global Colorectal Cancer Market Outlook, By Other Imaging Types (2021-2030) ($MN)
  • Table 25 Global Colorectal Cancer Market Outlook, By Other Modalities (2021-2030) ($MN)
  • Table 26 Global Colorectal Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Colorectal Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Colorectal Cancer Market Outlook, By Diagnostic and Research Laboratories (2021-2030) ($MN)
  • Table 29 Global Colorectal Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.